Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-Claudin18.2-transduced T lymphocytes CT041

A preparation of autologous T lymphocytes ex vivo transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CLDN18.2CAR-transduced T lymphocytes specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-Claudin18.2 CAR-T cells
autologous CAR-CLD18 T cells
autologous CAR-CLD18.2 T cells
Claudin18.2-redirected autologous cells
Claudin18.2-redirected autologous T cells
Code name:CT 041
CT-041
CT041
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search